 | • レポートコード：MRC2Q12-02149 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、105ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：化学&材料 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、ヒト血漿誘導体のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 ヒト血漿誘導体のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 ヒト血漿誘導体の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 ヒト血漿誘導体のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までのヒト血漿誘導体の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別のヒト血漿誘導体の売上および2028年までの予測に焦点を当てています。 ヒト血漿誘導体のグローバル主要企業には、CSL Behring、Baxalta (Takeda)、Grifols、Octapharma、SK Plasma、Fusion Health Care、Baxter International、Beijing Tiantan Biological Products Corporation、Hualan Biological、Shanghai RAAS Blood Products、Shandong Taibang Biological Products、China Resources Boya Bio-pharmaceutical Groupなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 ヒト血漿誘導体市場は、タイプとアプリケーションによって区分されます。世界のヒト血漿誘導体市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 アルブミン、血液凝固因子、免疫グロブリン、ハプトグロビン、C1不活性化剤 【アプリケーション別セグメント】 病院、診療所、生物学研究所、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - ヒト血漿誘導体製品概要 - タイプ別市場（アルブミン、血液凝固因子、免疫グロブリン、ハプトグロビン、C1不活性化剤） - アプリケーション別市場（病院、診療所、生物学研究所、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のヒト血漿誘導体販売量予測2017-2028 - 世界のヒト血漿誘導体売上予測2017-2028 - ヒト血漿誘導体の地域別販売量 - ヒト血漿誘導体の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別ヒト血漿誘導体販売量 - 主要メーカー別ヒト血漿誘導体売上 - 主要メーカー別ヒト血漿誘導体価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（アルブミン、血液凝固因子、免疫グロブリン、ハプトグロビン、C1不活性化剤） - ヒト血漿誘導体のタイプ別販売量 - ヒト血漿誘導体のタイプ別売上 - ヒト血漿誘導体のタイプ別価格 ・アプリケーション別市場規模（病院、診療所、生物学研究所、その他） - ヒト血漿誘導体のアプリケーション別販売量 - ヒト血漿誘導体のアプリケーション別売上 - ヒト血漿誘導体のアプリケーション別価格 ・北米市場 - 北米のヒト血漿誘導体市場規模（タイプ別、アプリケーション別） - 主要国別のヒト血漿誘導体市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのヒト血漿誘導体市場規模（タイプ別、アプリケーション別） - 主要国別のヒト血漿誘導体市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のヒト血漿誘導体市場規模（タイプ別、アプリケーション別） - 主要国別のヒト血漿誘導体市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のヒト血漿誘導体市場規模（タイプ別、アプリケーション別） - 主要国別のヒト血漿誘導体市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのヒト血漿誘導体市場規模（タイプ別、アプリケーション別） - 主要国別のヒト血漿誘導体市場規模（トルコ、サウジアラビア） ・企業情報 CSL Behring、Baxalta (Takeda)、Grifols、Octapharma、SK Plasma、Fusion Health Care、Baxter International、Beijing Tiantan Biological Products Corporation、Hualan Biological、Shanghai RAAS Blood Products、Shandong Taibang Biological Products、China Resources Boya Bio-pharmaceutical Group ・産業チェーン及び販売チャネル分析 - ヒト血漿誘導体の産業チェーン分析 - ヒト血漿誘導体の原材料 - ヒト血漿誘導体の生産プロセス - ヒト血漿誘導体の販売及びマーケティング - ヒト血漿誘導体の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - ヒト血漿誘導体の産業動向 - ヒト血漿誘導体のマーケットドライバー - ヒト血漿誘導体の課題 - ヒト血漿誘導体の阻害要因 ・主な調査結果 |
Plasma derivatives are products manufactured from human plasma by chromatographic and other fractionation techniques.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Human Plasma Derivative estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Human Plasma Derivative is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Human Plasma Derivative is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Human Plasma Derivative is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Human Plasma Derivative include CSL Behring, Baxalta (Takeda), Grifols, Octapharma, SK Plasma, Fusion Health Care, Baxter International, Beijing Tiantan Biological Products Corporation and Hualan Biological, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
In terms of production side, this report researches the Human Plasma Derivative production, growth rate, market share by manufacturers and by region (region level and country level), from 2017 to 2022, and forecast to 2028.
In terms of sales side, this report focuses on the sales of Human Plasma Derivative by region (region level and country level), by company, by Type and by Application. from 2017 to 2022 and forecast to 2028.
Report Scope
This latest report researches the industry structure, capacity, production, sales (consumption), revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Human Plasma Derivative manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Human Plasma Derivative market. Further, it explains the major drivers and regional dynamics of the global Human Plasma Derivative market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
CSL Behring
Baxalta (Takeda)
Grifols
Octapharma
SK Plasma
Fusion Health Care
Baxter International
Beijing Tiantan Biological Products Corporation
Hualan Biological
Shanghai RAAS Blood Products
Shandong Taibang Biological Products
China Resources Boya Bio-pharmaceutical Group
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on production, price, and value for the period 2017-2028.
Human Plasma Derivative Segment by Type
Albumin
Blood coagulation Factors
Immuno Globulins
Haptoglobin
C1-Inactivator
Human Plasma Derivative Segment by Application
Hospitals
Clinics
Biology Laboratory
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. This report analyzes the Human Plasma Derivative production by region/country, and the sales (consumption) by region/country. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Human Plasma Derivative market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Human Plasma Derivative, capacity, output, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Human Plasma Derivative, also provides the consumption of main regions and countries. Highlights of the upcoming market potential for Human Plasma Derivative, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Human Plasma Derivative sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Human Plasma Derivative market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Human Plasma Derivative sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including CSL Behring, Baxalta (Takeda), Grifols, Octapharma, SK Plasma, Fusion Health Care, Baxter International, Beijing Tiantan Biological Products Corporation and Hualan Biological, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Human Plasma Derivative capacity, production/output of global and key producers (regions/countries). It provides a quantitative analysis of the capacity, production, and development potential of each producer in the next six years.
Chapter 3: Sales (consumption), revenue of Human Plasma Derivative in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Human Plasma Derivative manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by type, by application and by country, sales and revenue for each segment.
Chapter 8: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 9: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 10: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 11: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 12: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Plasma Derivative sales, revenue, price, gross margin, and recent development, etc.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 15: The main points and conclusions of the report.
1 Study Coverage
1.1 Human Plasma Derivative Product Introduction
1.2 Market by Type
1.2.1 Global Human Plasma Derivative Market Size by Type, 2017 VS 2021 VS 2028
1.2.2 Albumin
1.2.3 Blood coagulation Factors
1.2.4 Immuno Globulins
1.2.5 Haptoglobin
1.2.6 C1-Inactivator
1.3 Market by Application
1.3.1 Global Human Plasma Derivative Market Size by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Biology Laboratory
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Human Plasma Derivative Production
2.1 Global Human Plasma Derivative Production Capacity (2017-2028)
2.2 Global Human Plasma Derivative Production by Region: 2017 VS 2021 VS 2028
2.3 Global Human Plasma Derivative Production by Region
2.3.1 Global Human Plasma Derivative Historic Production by Region (2017-2022)
2.3.2 Global Human Plasma Derivative Forecasted Production by Region (2023-2028)
2.4 North America
2.5 Europe
2.6 China
2.7 Japan
3 Global Human Plasma Derivative Sales in Volume & Value Estimates and Forecasts
3.1 Global Human Plasma Derivative Sales Estimates and Forecasts 2017-2028
3.2 Global Human Plasma Derivative Revenue Estimates and Forecasts 2017-2028
3.3 Global Human Plasma Derivative Revenue by Region: 2017 VS 2021 VS 2028
3.4 Global Human Plasma Derivative Sales by Region
3.4.1 Global Human Plasma Derivative Sales by Region (2017-2022)
3.4.2 Global Sales Human Plasma Derivative by Region (2023-2028)
3.5 Global Human Plasma Derivative Revenue by Region
3.5.1 Global Human Plasma Derivative Revenue by Region (2017-2022)
3.5.2 Global Human Plasma Derivative Revenue by Region (2023-2028)
3.6 North America
3.7 Europe
3.8 Asia-Pacific
3.9 Latin America
3.10 Middle East & Africa
4 Competition by Manufactures
4.1 Global Human Plasma Derivative Production Capacity by Manufacturers
4.2 Global Human Plasma Derivative Sales by Manufacturers
4.2.1 Global Human Plasma Derivative Sales by Manufacturers (2017-2022)
4.2.2 Global Human Plasma Derivative Sales Market Share by Manufacturers (2017-2022)
4.2.3 Global Top 10 and Top 5 Largest Manufacturers of Human Plasma Derivative in 2021
4.3 Global Human Plasma Derivative Revenue by Manufacturers
4.3.1 Global Human Plasma Derivative Revenue by Manufacturers (2017-2022)
4.3.2 Global Human Plasma Derivative Revenue Market Share by Manufacturers (2017-2022)
4.3.3 Global Top 10 and Top 5 Companies by Human Plasma Derivative Revenue in 2021
4.4 Global Human Plasma Derivative Sales Price by Manufacturers
4.5 Analysis of Competitive Landscape
4.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
4.5.2 Global Human Plasma Derivative Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5.3 Global Human Plasma Derivative Manufacturers Geographical Distribution
4.6 Mergers & Acquisitions, Expansion Plans
5 Market Size by Type
5.1 Global Human Plasma Derivative Sales by Type
5.1.1 Global Human Plasma Derivative Historical Sales by Type (2017-2022)
5.1.2 Global Human Plasma Derivative Forecasted Sales by Type (2023-2028)
5.1.3 Global Human Plasma Derivative Sales Market Share by Type (2017-2028)
5.2 Global Human Plasma Derivative Revenue by Type
5.2.1 Global Human Plasma Derivative Historical Revenue by Type (2017-2022)
5.2.2 Global Human Plasma Derivative Forecasted Revenue by Type (2023-2028)
5.2.3 Global Human Plasma Derivative Revenue Market Share by Type (2017-2028)
5.3 Global Human Plasma Derivative Price by Type
5.3.1 Global Human Plasma Derivative Price by Type (2017-2022)
5.3.2 Global Human Plasma Derivative Price Forecast by Type (2023-2028)
6 Market Size by Application
6.1 Global Human Plasma Derivative Sales by Application
6.1.1 Global Human Plasma Derivative Historical Sales by Application (2017-2022)
6.1.2 Global Human Plasma Derivative Forecasted Sales by Application (2023-2028)
6.1.3 Global Human Plasma Derivative Sales Market Share by Application (2017-2028)
6.2 Global Human Plasma Derivative Revenue by Application
6.2.1 Global Human Plasma Derivative Historical Revenue by Application (2017-2022)
6.2.2 Global Human Plasma Derivative Forecasted Revenue by Application (2023-2028)
6.2.3 Global Human Plasma Derivative Revenue Market Share by Application (2017-2028)
6.3 Global Human Plasma Derivative Price by Application
6.3.1 Global Human Plasma Derivative Price by Application (2017-2022)
6.3.2 Global Human Plasma Derivative Price Forecast by Application (2023-2028)
7 North America
7.1 North America Human Plasma Derivative Market Size by Type
7.1.1 North America Human Plasma Derivative Sales by Type (2017-2028)
7.1.2 North America Human Plasma Derivative Revenue by Type (2017-2028)
7.2 North America Human Plasma Derivative Market Size by Application
7.2.1 North America Human Plasma Derivative Sales by Application (2017-2028)
7.2.2 North America Human Plasma Derivative Revenue by Application (2017-2028)
7.3 North America Human Plasma Derivative Sales by Country
7.3.1 North America Human Plasma Derivative Sales by Country (2017-2028)
7.3.2 North America Human Plasma Derivative Revenue by Country (2017-2028)
7.3.3 United States
7.3.4 Canada
8 Europe
8.1 Europe Human Plasma Derivative Market Size by Type
8.1.1 Europe Human Plasma Derivative Sales by Type (2017-2028)
8.1.2 Europe Human Plasma Derivative Revenue by Type (2017-2028)
8.2 Europe Human Plasma Derivative Market Size by Application
8.2.1 Europe Human Plasma Derivative Sales by Application (2017-2028)
8.2.2 Europe Human Plasma Derivative Revenue by Application (2017-2028)
8.3 Europe Human Plasma Derivative Sales by Country
8.3.1 Europe Human Plasma Derivative Sales by Country (2017-2028)
8.3.2 Europe Human Plasma Derivative Revenue by Country (2017-2028)
8.3.3 Germany
8.3.4 France
8.3.5 U.K.
8.3.6 Italy
8.3.7 Russia
9 Asia Pacific
9.1 Asia Pacific Human Plasma Derivative Market Size by Type
9.1.1 Asia Pacific Human Plasma Derivative Sales by Type (2017-2028)
9.1.2 Asia Pacific Human Plasma Derivative Revenue by Type (2017-2028)
9.2 Asia Pacific Human Plasma Derivative Market Size by Application
9.2.1 Asia Pacific Human Plasma Derivative Sales by Application (2017-2028)
9.2.2 Asia Pacific Human Plasma Derivative Revenue by Application (2017-2028)
9.3 Asia Pacific Human Plasma Derivative Sales by Region
9.3.1 Asia Pacific Human Plasma Derivative Sales by Region (2017-2028)
9.3.2 Asia Pacific Human Plasma Derivative Revenue by Region (2017-2028)
9.3.3 China
9.3.4 Japan
9.3.5 South Korea
9.3.6 India
9.3.7 Australia
9.3.8 China Taiwan
9.3.9 Indonesia
9.3.10 Thailand
9.3.11 Malaysia
10 Latin America
10.1 Latin America Human Plasma Derivative Market Size by Type
10.1.1 Latin America Human Plasma Derivative Sales by Type (2017-2028)
10.1.2 Latin America Human Plasma Derivative Revenue by Type (2017-2028)
10.2 Latin America Human Plasma Derivative Market Size by Application
10.2.1 Latin America Human Plasma Derivative Sales by Application (2017-2028)
10.2.2 Latin America Human Plasma Derivative Revenue by Application (2017-2028)
10.3 Latin America Human Plasma Derivative Sales by Country
10.3.1 Latin America Human Plasma Derivative Sales by Country (2017-2028)
10.3.2 Latin America Human Plasma Derivative Revenue by Country (2017-2028)
10.3.3 Mexico
10.3.4 Brazil
10.3.5 Argentina
10.3.6 Colombia
11 Middle East and Africa
11.1 Middle East and Africa Human Plasma Derivative Market Size by Type
11.1.1 Middle East and Africa Human Plasma Derivative Sales by Type (2017-2028)
11.1.2 Middle East and Africa Human Plasma Derivative Revenue by Type (2017-2028)
11.2 Middle East and Africa Human Plasma Derivative Market Size by Application
11.2.1 Middle East and Africa Human Plasma Derivative Sales by Application (2017-2028)
11.2.2 Middle East and Africa Human Plasma Derivative Revenue by Application (2017-2028)
11.3 Middle East and Africa Human Plasma Derivative Sales by Country
11.3.1 Middle East and Africa Human Plasma Derivative Sales by Country (2017-2028)
11.3.2 Middle East and Africa Human Plasma Derivative Revenue by Country (2017-2028)
11.3.3 Turkey
11.3.4 Saudi Arabia
11.3.5 UAE
12 Corporate Profiles
12.1 CSL Behring
12.1.1 CSL Behring Corporation Information
12.1.2 CSL Behring Overview
12.1.3 CSL Behring Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.1.4 CSL Behring Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.1.5 CSL Behring Recent Developments
12.2 Baxalta (Takeda)
12.2.1 Baxalta (Takeda) Corporation Information
12.2.2 Baxalta (Takeda) Overview
12.2.3 Baxalta (Takeda) Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.2.4 Baxalta (Takeda) Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.2.5 Baxalta (Takeda) Recent Developments
12.3 Grifols
12.3.1 Grifols Corporation Information
12.3.2 Grifols Overview
12.3.3 Grifols Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.3.4 Grifols Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.3.5 Grifols Recent Developments
12.4 Octapharma
12.4.1 Octapharma Corporation Information
12.4.2 Octapharma Overview
12.4.3 Octapharma Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.4.4 Octapharma Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.4.5 Octapharma Recent Developments
12.5 SK Plasma
12.5.1 SK Plasma Corporation Information
12.5.2 SK Plasma Overview
12.5.3 SK Plasma Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.5.4 SK Plasma Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.5.5 SK Plasma Recent Developments
12.6 Fusion Health Care
12.6.1 Fusion Health Care Corporation Information
12.6.2 Fusion Health Care Overview
12.6.3 Fusion Health Care Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.6.4 Fusion Health Care Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.6.5 Fusion Health Care Recent Developments
12.7 Baxter International
12.7.1 Baxter International Corporation Information
12.7.2 Baxter International Overview
12.7.3 Baxter International Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.7.4 Baxter International Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.7.5 Baxter International Recent Developments
12.8 Beijing Tiantan Biological Products Corporation
12.8.1 Beijing Tiantan Biological Products Corporation Corporation Information
12.8.2 Beijing Tiantan Biological Products Corporation Overview
12.8.3 Beijing Tiantan Biological Products Corporation Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.8.4 Beijing Tiantan Biological Products Corporation Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.8.5 Beijing Tiantan Biological Products Corporation Recent Developments
12.9 Hualan Biological
12.9.1 Hualan Biological Corporation Information
12.9.2 Hualan Biological Overview
12.9.3 Hualan Biological Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.9.4 Hualan Biological Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.9.5 Hualan Biological Recent Developments
12.10 Shanghai RAAS Blood Products
12.10.1 Shanghai RAAS Blood Products Corporation Information
12.10.2 Shanghai RAAS Blood Products Overview
12.10.3 Shanghai RAAS Blood Products Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.10.4 Shanghai RAAS Blood Products Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.10.5 Shanghai RAAS Blood Products Recent Developments
12.11 Shandong Taibang Biological Products
12.11.1 Shandong Taibang Biological Products Corporation Information
12.11.2 Shandong Taibang Biological Products Overview
12.11.3 Shandong Taibang Biological Products Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.11.4 Shandong Taibang Biological Products Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.11.5 Shandong Taibang Biological Products Recent Developments
12.12 China Resources Boya Bio-pharmaceutical Group
12.12.1 China Resources Boya Bio-pharmaceutical Group Corporation Information
12.12.2 China Resources Boya Bio-pharmaceutical Group Overview
12.12.3 China Resources Boya Bio-pharmaceutical Group Human Plasma Derivative Sales, Price, Revenue and Gross Margin (2017-2022)
12.12.4 China Resources Boya Bio-pharmaceutical Group Human Plasma Derivative Product Model Numbers, Pictures, Descriptions and Specifications
12.12.5 China Resources Boya Bio-pharmaceutical Group Recent Developments
13 Industry Chain and Sales Channels Analysis
13.1 Human Plasma Derivative Industry Chain Analysis
13.2 Human Plasma Derivative Key Raw Materials
13.2.1 Key Raw Materials
13.2.2 Raw Materials Key Suppliers
13.3 Human Plasma Derivative Production Mode & Process
13.4 Human Plasma Derivative Sales and Marketing
13.4.1 Human Plasma Derivative Sales Channels
13.4.2 Human Plasma Derivative Distributors
13.5 Human Plasma Derivative Customers
14 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
14.1 Human Plasma Derivative Industry Trends
14.2 Human Plasma Derivative Market Drivers
14.3 Human Plasma Derivative Market Challenges
14.4 Human Plasma Derivative Market Restraints
15 Key Finding in The Global Human Plasma Derivative Study
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer